{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:35:57Z","timestamp":1794638157893,"version":"4.9.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-66073-4","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:05:01Z","timestamp":1765613101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0912-2632","authenticated-orcid":false,"given":"Ji","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3527-1145","authenticated-orcid":false,"given":"Bert","family":"Malengier-Devlies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babs E.","family":"Verstrepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1959-5393","authenticated-orcid":false,"given":"Yeranddy A.","family":"Alpizar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vercruysse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahadesh Prasad Arkalagud","family":"Javarappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-0931","authenticated-orcid":false,"given":"Lorena","family":"Sanchez-Felipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3428-5978","authenticated-orcid":false,"given":"Gerrit","family":"Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-9345","authenticated-orcid":false,"given":"Natasja G.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9685-6836","authenticated-orcid":false,"given":"Patrick","family":"Matthys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0033-7514","authenticated-orcid":false,"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0912-2074","authenticated-orcid":false,"given":"Ernst J.","family":"Verschoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7888-4534","authenticated-orcid":false,"given":"Lotte","family":"Coelmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-8276","authenticated-orcid":false,"given":"Hendrik Jan","family":"Thibaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3234-8426","authenticated-orcid":false,"given":"Johan","family":"Van Weyenbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8117-9166","authenticated-orcid":false,"given":"Kai","family":"Dallmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"66073_CR1","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1021\/acs.chemrev.7b00719","volume":"118","author":"NJ Barrows","year":"2018","unstructured":"Barrows, N. J. et al. Biochemistry and molecular biology of flaviviruses. Chem. Rev. 118, 4448\u20134482 (2018).","journal-title":"Chem. Rev."},{"key":"66073_CR2","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1056\/NEJMra1808246","volume":"381","author":"D Musso","year":"2019","unstructured":"Musso, D., Ko, A. I. & Baud, D. Zika virus infection - after the pandemic. N. Engl. J. Med. 381, 1444\u20131457 (2019).","journal-title":"N. Engl. J. Med."},{"key":"66073_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.chom.2018.05.021","volume":"24","author":"C Shan","year":"2018","unstructured":"Shan, C., Xie, X. & Shi, P. Y. Zika virus vaccine: progress and challenges. Cell Host Microbe 24, 12\u201317 (2018).","journal-title":"Cell Host Microbe"},{"key":"66073_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.immuni.2017.02.005","volume":"46","author":"DH Barouch","year":"2017","unstructured":"Barouch, D. H., Thomas, S. J. & Michael, N. L. Prospects for a Zika virus vaccine. Immunity 46, 176\u2013182 (2017).","journal-title":"Immunity"},{"key":"66073_CR5","first-page":"1026","volume":"112","author":"IB Rabe","year":"2025","unstructured":"Rabe, I. B. et al. A review of the recent epidemiology of Zika virus infection. Am. J. Trop. Med. Hyg. 112, 1026\u20131035 (2025).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"66073_CR6","doi-asserted-by":"crossref","unstructured":"Ostrowsky, J. T. et al. Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development. Lancet Infect Dis. 25, e402\u2013e415 (2025).","DOI":"10.1016\/S1473-3099(24)00750-3"},{"key":"66073_CR7","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1016\/j.vaccine.2007.02.079","volume":"25","author":"J Hombach","year":"2007","unstructured":"Hombach, J., Cardosa, M. J., Sabchareon, A., Vaughn, D. W. & Barrett, A. D. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 25, 4130\u20134139 (2007).","journal-title":"Vaccine"},{"key":"66073_CR8","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1093\/infdis\/jiz379","volume":"221","author":"ADT Barrett","year":"2020","unstructured":"Barrett, A. D. T. Yellow fever vaccine: the conundrum of 2 doses, one dose, or one-fifth dose to induce and maintain protective immunity. J. Infect. Dis. 221, 1922\u20131924 (2020).","journal-title":"J. Infect. Dis."},{"key":"66073_CR9","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.aah6157","volume":"353","author":"P Abbink","year":"2016","unstructured":"Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129\u20131132 (2016).","journal-title":"Science"},{"key":"66073_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao4163","volume":"9","author":"P Abbink","year":"2017","unstructured":"Abbink, P. et al. Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci. Transl. Med. 9, eaao4163 (2017).","journal-title":"Sci. Transl. Med."},{"key":"66073_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1126\/science.aai9137","volume":"354","author":"KA Dowd","year":"2016","unstructured":"Dowd, K. A. et al. Rapid development of a DNA vaccine for Zika virus. Science 354, 237\u2013240 (2016).","journal-title":"Science"},{"key":"66073_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw9066","volume":"12","author":"S Maciejewski","year":"2020","unstructured":"Maciejewski, S. et al. Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Sci. Transl. Med. 12, eaaw9066 (2020).","journal-title":"Sci. Transl. Med."},{"key":"66073_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature18952","volume":"536","author":"RA Larocca","year":"2016","unstructured":"Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474\u2013478 (2016).","journal-title":"Nature"},{"key":"66073_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01429-24","volume":"98","author":"JP Nkolola","year":"2024","unstructured":"Nkolola, J. P. et al. Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques. J. Virol. 98, e0142924 (2024).","journal-title":"J. Virol."},{"key":"66073_CR15","doi-asserted-by":"publisher","first-page":"e0004682","DOI":"10.1371\/journal.pntd.0004682","volume":"10","author":"MT Aliota","year":"2016","unstructured":"Aliota, M. T. et al. Characterization of lethal Zika virus infection in AG129 mice. PLoS Negl. Trop. Dis. 10, e0004682 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"66073_CR16","doi-asserted-by":"publisher","first-page":"e0004695","DOI":"10.1371\/journal.pntd.0004695","volume":"10","author":"J Zmurko","year":"2016","unstructured":"Zmurko, J. et al. The viral polymerase inhibitor 7-deaza-2\u2019-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl. Trop. Dis. 10, e0004695 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"66073_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05519-4","volume":"9","author":"CGO Lucas","year":"2018","unstructured":"Lucas, C. G. O. et al. Critical role of CD4(+) T cells and IFNgamma signaling in antibody-mediated resistance to Zika virus infection. Nat. Commun. 9, 3136 (2018).","journal-title":"Nat. Commun."},{"key":"66073_CR18","doi-asserted-by":"publisher","first-page":"e1007237","DOI":"10.1371\/journal.ppat.1007237","volume":"14","author":"M Hassert","year":"2018","unstructured":"Hassert, M. et al. CD4+T cells mediate protection against Zika associated severe disease in a mouse model of infection. PLoS Pathog. 14, e1007237 (2018).","journal-title":"PLoS Pathog."},{"key":"66073_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb2154","volume":"6","author":"A Elong Ngono","year":"2020","unstructured":"Elong Ngono, A. et al. CD8(+) T cells mediate protection against Zika virus induced by an NS3-based vaccine. Sci. Adv. 6, eabb2154 (2020).","journal-title":"Sci. Adv."},{"key":"66073_CR20","doi-asserted-by":"publisher","first-page":"e1007474","DOI":"10.1371\/journal.ppat.1007474","volume":"15","author":"A Elong Ngono","year":"2019","unstructured":"Elong Ngono, A. et al. CD4+ T cells promote humoral immunity and viral control during Zika virus infection. PLoS Pathog. 15, e1007474 (2019).","journal-title":"PLoS Pathog."},{"key":"66073_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax2388","volume":"5","author":"B Grubor-Bauk","year":"2019","unstructured":"Grubor-Bauk, B. et al. NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice. Sci. Adv. 5, eaax2388 (2019).","journal-title":"Sci. Adv."},{"key":"66073_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0092-2","volume":"3","author":"DB Kum","year":"2018","unstructured":"Kum, D. B. et al. A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice. NPJ Vaccines 3, 56 (2018).","journal-title":"NPJ Vaccines"},{"key":"66073_CR23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.it.2017.05.004","volume":"38","author":"NS Lima","year":"2017","unstructured":"Lima, N. S., Rolland, M., Modjarrad, K. & Trautmann, L. T cell immunity and Zika virus vaccine development. Trends Immunol. 38, 594\u2013605 (2017).","journal-title":"Trends Immunol."},{"key":"66073_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri2629","volume":"9","author":"B Pulendran","year":"2009","unstructured":"Pulendran, B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9, 741\u2013747 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"66073_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/imr.12099","volume":"255","author":"B Pulendran","year":"2013","unstructured":"Pulendran, B., Oh, J. Z., Nakaya, H. I., Ravindran, R. & Kazmin, D. A. Immunity to viruses: learning from successful human vaccines. Immunol. Rev. 255, 243\u2013255 (2013).","journal-title":"Immunol. Rev."},{"key":"66073_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ni.1688","volume":"10","author":"TD Querec","year":"2009","unstructured":"Querec, T. D. et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116\u2013125 (2009).","journal-title":"Nat. Immunol."},{"key":"66073_CR27","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1517\/14712598.2012.704908","volume":"12","author":"MB Appaiahgari","year":"2012","unstructured":"Appaiahgari, M. B. & Vrati, S. Clinical development of IMOJEV (R)-a recombinant Japanese encephalitis chimeric vaccine (JE-CV). Expert Opin. Biol. Ther. 12, 1251\u20131263 (2012).","journal-title":"Expert Opin. Biol. Ther."},{"key":"66073_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2017.1335201","volume":"16","author":"B Guy","year":"2017","unstructured":"Guy, B. et al. A recombinant live attenuated tetravalent vaccine for the prevention of dengue. Expert Rev. Vaccines 16, 1\u201313 (2017).","journal-title":"Expert Rev. Vaccines"},{"key":"66073_CR29","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.4161\/hv.28117","volume":"10","author":"MC Bonaldo","year":"2014","unstructured":"Bonaldo, M. C., Sequeira, P. C. & Galler, R. The yellow fever 17D virus as a platform for new live attenuated vaccines. Hum. Vaccin Immunother. 10, 1256\u20131265 (2014).","journal-title":"Hum. Vaccin Immunother."},{"key":"66073_CR30","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/s41590-022-01329-5","volume":"23","author":"S Fourati","year":"2022","unstructured":"Fourati, S. et al. Pan-vaccine analysis reveals innate immune endotypes predictive of antibody responses to vaccination. Nat. Immunol. 23, 1777\u20131787 (2022).","journal-title":"Nat. Immunol."},{"key":"66073_CR31","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1084\/jem.20082292","volume":"205","author":"D Gaucher","year":"2008","unstructured":"Gaucher, D. et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205, 3119\u20133131 (2008).","journal-title":"J. Exp. Med."},{"key":"66073_CR32","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/s41590-022-01328-6","volume":"23","author":"T Hagan","year":"2022","unstructured":"Hagan, T. et al. Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses. Nat. Immunol. 23, 1788\u20131798 (2022).","journal-title":"Nat. Immunol."},{"key":"66073_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1084\/jem.20051720","volume":"203","author":"T Querec","year":"2006","unstructured":"Querec, T. et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203, 413\u2013424 (2006).","journal-title":"J. Exp. Med."},{"key":"66073_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12204","volume":"7","author":"DM Dudley","year":"2016","unstructured":"Dudley, D. M. et al. A rhesus macaque model of Asian-lineage Zika virus infection. Nat. Commun. 7, 12204 (2016).","journal-title":"Nat. Commun."},{"key":"66073_CR35","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/nm.4206","volume":"22","author":"CE Osuna","year":"2016","unstructured":"Osuna, C. E. et al. Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat. Med. 22, 1448\u20131455 (2016).","journal-title":"Nat. Med."},{"key":"66073_CR36","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/vaccines12070755","volume":"12","author":"S Gobel","year":"2024","unstructured":"Gobel, S. et al. Parallel multifactorial process optimization and intensification for high-yield production of live YF17D-vectored Zika vaccine. Vaccines (Basel) 12, 755 (2024).","journal-title":"Vaccines (Basel)"},{"key":"66073_CR37","doi-asserted-by":"publisher","first-page":"e2250133","DOI":"10.1002\/eji.202250133","volume":"54","author":"L Sanchez-Felipe","year":"2024","unstructured":"Sanchez-Felipe, L., Alpizar, Y. A., Ma, J., Coelmont, L. & Dallmeier, K. YF17D-based vaccines - standing on the shoulders of a giant. Eur. J. Immunol. 54, e2250133 (2024).","journal-title":"Eur. J. Immunol."},{"key":"66073_CR38","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1073\/pnas.1500475112","volume":"112","author":"RS Akondy","year":"2015","unstructured":"Akondy, R. S. et al. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. Proc. Natl. Acad. Sci. USA 112, 3050\u20133055 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66073_CR39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41564-024-01903-7","volume":"10","author":"S Kalimuddin","year":"2025","unstructured":"Kalimuddin, S. et al. Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans. Nat. Microbiol. 10, 374\u2013387 (2025).","journal-title":"Nat. Microbiol."},{"key":"66073_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01516-23","volume":"98","author":"N Mantel","year":"2024","unstructured":"Mantel, N. et al. Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination. J. Virol. 98, e0151623 (2024).","journal-title":"J. Virol."},{"key":"66073_CR41","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00251-010-0461-0","volume":"62","author":"PA Mudd","year":"2010","unstructured":"Mudd, P. A. et al. The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques-implications for recombinant vaccine design. Immunogenetics 62, 593\u2013600 (2010).","journal-title":"Immunogenetics"},{"key":"66073_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.chom.2016.12.010","volume":"21","author":"A Elong Ngono","year":"2017","unstructured":"Elong Ngono, A. et al. Mapping and role of the CD8(+) T cell response during primary Zika virus infection in mice. Cell Host Microbe 21, 35\u201346 (2017).","journal-title":"Cell Host Microbe"},{"key":"66073_CR43","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1080\/22221751.2020.1730709","volume":"9","author":"DB Kum","year":"2020","unstructured":"Kum, D. B. et al. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice. Emerg. Microbes Infect. 9, 520\u2013533 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"66073_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4896","volume":"376","author":"C Tabula Sapiens","year":"2022","unstructured":"Tabula Sapiens, C. et al. The tabula sapiens: a multiple-organ, single-cell transcriptomic atlas of humans. Science 376, eabl4896 (2022).","journal-title":"Science"},{"key":"66073_CR45","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1189\/jlb.0907609","volume":"83","author":"L Meyaard","year":"2008","unstructured":"Meyaard, L. The inhibitory collagen receptor LAIR-1 (CD305). J. Leukoc. Biol. 83, 799\u2013803 (2008).","journal-title":"J. Leukoc. Biol."},{"key":"66073_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03337-2","volume":"9","author":"SS Kwek","year":"2018","unstructured":"Kwek, S. S. et al. A systematic approach to the development of a safe live attenuated Zika vaccine. Nat. Commun. 9, 1031 (2018).","journal-title":"Nat. Commun."},{"key":"66073_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0167-8","volume":"5","author":"V Lecouturier","year":"2020","unstructured":"Lecouturier, V. et al. An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques. NPJ Vaccines 5, 19 (2020).","journal-title":"NPJ Vaccines"},{"key":"66073_CR48","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3390\/microorganisms12061177","volume":"12","author":"CJ Acosta","year":"2024","unstructured":"Acosta, C. J. et al. Predicting efficacy of a purified inactivated Zika virus vaccine in flavivirus-naive humans using an immunological correlate of protection in non-human primates. Microorganisms 12, 1177 (2024).","journal-title":"Microorganisms"},{"key":"66073_CR49","doi-asserted-by":"publisher","first-page":"e00038","DOI":"10.1128\/JVI.00038-18","volume":"92","author":"JM Scott","year":"2018","unstructured":"Scott, J. M. et al. Cellular and humoral immunity protect against vaginal Zika virus infection in mice. J. Virol. 92, e00038\u201300018 (2018).","journal-title":"J. Virol."},{"key":"66073_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00699-7","volume":"8","author":"V Lemmens","year":"2023","unstructured":"Lemmens, V. et al. YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge. NPJ Vaccines 8, 99 (2023).","journal-title":"NPJ Vaccines"},{"key":"66073_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104240","volume":"83","author":"J Ma","year":"2022","unstructured":"Ma, J. et al. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models. EBioMedicine 83, 104240 (2022).","journal-title":"EBioMedicine"},{"key":"66073_CR52","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41586-020-3035-9","volume":"590","author":"L Sanchez-Felipe","year":"2021","unstructured":"Sanchez-Felipe, L. et al. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature 590, 320\u2013325 (2021).","journal-title":"Nature"},{"key":"66073_CR53","doi-asserted-by":"publisher","first-page":"e01970","DOI":"10.1128\/JVI.01970-16","volume":"91","author":"SM Best","year":"2017","unstructured":"Best, S. M. The many faces of the flavivirus NS5 protein in antagonism of type I interferon signaling. J. Virol. 91, e01970\u201301916 (2017).","journal-title":"J. Virol."},{"key":"66073_CR54","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.chom.2014.07.015","volume":"16","author":"M Laurent-Rolle","year":"2014","unstructured":"Laurent-Rolle, M. et al. The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon. Cell Host Microbe 16, 314\u2013327 (2014).","journal-title":"Cell Host Microbe"},{"key":"66073_CR55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202486","volume":"218","author":"P Bastard","year":"2021","unstructured":"Bastard, P. et al. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J. Exp. Med. 218, e20202486 (2021).","journal-title":"J. Exp. Med."},{"key":"66073_CR56","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1084\/jem.20182295","volume":"216","author":"N Hernandez","year":"2019","unstructured":"Hernandez, N. et al. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. J. Exp. Med. 216, 2057\u20132070 (2019).","journal-title":"J. Exp. Med."},{"key":"66073_CR57","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.vaccine.2020.01.045","volume":"38","author":"A Bovay","year":"2020","unstructured":"Bovay, A. et al. Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies. Vaccine 38, 2172\u20132182 (2020).","journal-title":"Vaccine"},{"key":"66073_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00798-1","volume":"7","author":"M Kongsgaard","year":"2017","unstructured":"Kongsgaard, M. et al. Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination. Sci. Rep. 7, 662 (2017).","journal-title":"Sci. Rep."},{"key":"66073_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02222-8","volume":"8","author":"DM Dudley","year":"2017","unstructured":"Dudley, D. M. et al. Infection via mosquito bite alters Zika virus tissue tropism and replication kinetics in rhesus macaques. Nat. Commun. 8, 2096 (2017).","journal-title":"Nat. Commun."},{"key":"66073_CR60","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20564","volume":"540","author":"G Sapparapu","year":"2016","unstructured":"Sapparapu, G. et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443\u2013447 (2016).","journal-title":"Nature"},{"key":"66073_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00737-8","volume":"8","author":"C Shan","year":"2017","unstructured":"Shan, C. et al. A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. Nat. Commun. 8, 676 (2017).","journal-title":"Nat. Commun."},{"key":"66073_CR62","doi-asserted-by":"crossref","unstructured":"Li, A. et al. Role of non-human primate models in accelerating research and developing countermeasures against Zika virus infection. Lancet Microbe. 6, 101030 (2025).","DOI":"10.1016\/j.lanmic.2024.101030"},{"key":"66073_CR63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay2736","volume":"11","author":"KKA Van Rompay","year":"2019","unstructured":"Van Rompay, K. K. A. et al. DNA vaccination before conception protects Zika virus-exposed pregnant macaques against prolonged viremia and improves fetal outcomes. Sci. Transl. Med. 11, eaay2736 (2019).","journal-title":"Sci. Transl. Med."},{"key":"66073_CR64","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","volume":"21","author":"F Mackay","year":"2003","unstructured":"Mackay, F., Schneider, P., Rennert, P. & Browning, J. BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231\u2013264 (2003).","journal-title":"Annu. Rev. Immunol."},{"key":"66073_CR65","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh2624","volume":"13","author":"MGP van der Wijst","year":"2021","unstructured":"van der Wijst, M. G. P. et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci. Transl. Med. 13, eabh2624 (2021).","journal-title":"Sci. Transl. Med."},{"key":"66073_CR66","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s43587-023-00421-1","volume":"3","author":"L Cuypers","year":"2023","unstructured":"Cuypers, L. et al. Immunovirological and environmental screening reveals actionable risk factors for fatal COVID-19 during post-vaccination nursing home outbreaks. Nat. Aging 3, 722\u2013733 (2023).","journal-title":"Nat. Aging"},{"key":"66073_CR67","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/vaccines9060622","volume":"9","author":"KL Carpio","year":"2021","unstructured":"Carpio, K. L. & Barrett, A. D. T. Flavivirus NS1 and its potential in vaccine development. Vaccines (Basel) 9, 622 (2021).","journal-title":"Vaccines (Basel)"},{"key":"66073_CR68","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.vaccine.2014.10.004","volume":"33","author":"TP Monath","year":"2015","unstructured":"Monath, T. P. et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk\/benefit assessment. Vaccine 33, 62\u201372 (2015).","journal-title":"Vaccine"},{"key":"66073_CR69","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1086\/378356","volume":"188","author":"TP Monath","year":"2003","unstructured":"Monath, T. P. et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188, 1213\u20131230 (2003).","journal-title":"J. Infect. Dis."},{"key":"66073_CR70","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1128\/JVI.74.4.1742-1751.2000","volume":"74","author":"TP Monath","year":"2000","unstructured":"Monath, T. P. et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. Virol. 74, 1742\u20131751 (2000).","journal-title":"J. Virol."},{"key":"66073_CR71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/infdis\/jiq003","volume":"203","author":"R Biedenbender","year":"2011","unstructured":"Biedenbender, R., Bevilacqua, J., Gregg, A. M., Watson, M. & Dayan, G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203, 75\u201384 (2011).","journal-title":"J. Infect. Dis."},{"key":"66073_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-391","volume":"14","author":"AC Campi-Azevedo","year":"2014","unstructured":"Campi-Azevedo, A. C. et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological\/immunological kinetics timeline. BMC Infect. Dis. 14, 391 (2014).","journal-title":"BMC Infect. Dis."},{"key":"66073_CR73","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1016\/j.vaccine.2012.08.063","volume":"30","author":"GH Dayan","year":"2012","unstructured":"Dayan, G. H., Bevilacqua, J., Coleman, D., Buldo, A. & Risi, G. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults >\/= 50 years of age. Vaccine 30, 6656\u20136664 (2012).","journal-title":"Vaccine"},{"key":"66073_CR74","doi-asserted-by":"publisher","first-page":"6694","DOI":"10.1073\/pnas.0601932103","volume":"103","author":"TP Monath","year":"2006","unstructured":"Monath, T. P. et al. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl. Acad. Sci. USA 103, 6694\u20136699 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66073_CR75","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0140-6736(20)32520-4","volume":"397","author":"A Juan-Giner","year":"2021","unstructured":"Juan-Giner, A. et al. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet 397, 119\u2013127 (2021).","journal-title":"Lancet"},{"key":"66073_CR76","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1056\/NEJMoa2407293","volume":"392","author":"D Kimathi","year":"2025","unstructured":"Kimathi, D. et al. Low-dose yellow fever vaccine in adults in Africa. N. Engl. J. Med. 392, 788\u2013797 (2025).","journal-title":"N. Engl. J. Med."},{"key":"66073_CR77","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1080\/22221751.2019.1694394","volume":"8","author":"DB Kum","year":"2019","unstructured":"Kum, D. B. et al. Limited evolution of the yellow fever virus 17d in a mouse infection model. Emerg. Microbes Infect. 8, 1734\u20131746 (2019).","journal-title":"Emerg. Microbes Infect."},{"key":"66073_CR78","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00006231-199203000-00002","volume":"13","author":"NP Verhoeff","year":"1992","unstructured":"Verhoeff, N. P. et al. Focus localization in patients with partial epilepsy with 99Tcm-HMPAO SPECT under continuous surface EEG monitoring. Nucl. Med. Commun. 13, 127\u2013136 (1992).","journal-title":"Nucl. Med. Commun."},{"key":"66073_CR79","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.abb6143","volume":"369","author":"LC Katzelnick","year":"2020","unstructured":"Katzelnick, L. C. et al. Zika virus infection enhances future risk of severe dengue disease. Science 369, 1123\u20131128 (2020).","journal-title":"Science"},{"key":"66073_CR80","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn2199","volume":"16","author":"JV Zambrana","year":"2024","unstructured":"Zambrana, J. V. et al. Primary exposure to Zika virus is linked with increased risk of symptomatic dengue virus infection with serotypes 2, 3, and 4, but not 1. Sci. Transl. Med. 16, eadn2199 (2024).","journal-title":"Sci. Transl. Med."},{"key":"66073_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00658-2","volume":"8","author":"SJ Thomas","year":"2023","unstructured":"Thomas, S. J. Is new dengue vaccine efficacy data a relief or cause for concern? NPJ Vaccines 8, 55 (2023).","journal-title":"NPJ Vaccines"},{"key":"66073_CR82","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1473-3099(24)00434-1","volume":"24","author":"AB Wilder-Smith","year":"2024","unstructured":"Wilder-Smith, A. B., Freedman, D. O. & Wilder-Smith, A. Edging towards a third dengue vaccine. Lancet Infect. Dis. 24, 1182\u20131184 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"66073_CR83","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4269\/ajtmh.20-0635","volume":"104","author":"B Zambrano","year":"2021","unstructured":"Zambrano, B. et al. Zika and dengue interactions in the context of a large dengue vaccine clinical trial in Latin America. Am. J. Trop. Med. Hyg. 104, 136\u2013144 (2021).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"66073_CR84","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3390\/vaccines13050483","volume":"13","author":"A Wilder-Smith","year":"2025","unstructured":"Wilder-Smith, A., Cherian, T. & Hombach, J. Dengue vaccine development and deployment into routine immunization. Vaccines (Basel) 13, 483 (2025).","journal-title":"Vaccines (Basel)"},{"key":"66073_CR85","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3390\/vaccines13070757","volume":"13","author":"S Gobel","year":"2025","unstructured":"Gobel, S. et al. Optimization of YF17D-vectored Zika vaccine production by employing small-molecule viral sensitizers to enhance yields. Vaccines (Basel) 13, 757 (2025).","journal-title":"Vaccines (Basel)"},{"key":"66073_CR86","first-page":"30159","volume":"21","author":"L Barzon","year":"2016","unstructured":"Barzon, L. et al. Isolation of infectious Zika virus from saliva and prolonged viral RNA shedding in a traveller returning from the Dominican Republic to Italy, January 2016. Eur. Surveill. 21, 30159 (2016).","journal-title":"Eur. Surveill."},{"key":"66073_CR87","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02548-21","volume":"10","author":"M Rasulova","year":"2022","unstructured":"Rasulova, M. et al. A high-throughput yellow fever neutralization assay. Microbiol. Spectr. 10, e0254821 (2022).","journal-title":"Microbiol. Spectr."},{"key":"66073_CR88","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S2213-2600(22)00259-4","volume":"10","author":"S Feys","year":"2022","unstructured":"Feys, S. et al. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study. Lancet Respir. Med. 10, 1147\u20131159 (2022).","journal-title":"Lancet Respir. Med."},{"key":"66073_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00055-7","volume":"5","author":"SM Menezes","year":"2024","unstructured":"Menezes, S. M. et al. Blood transcriptomic analyses reveal persistent SARS-CoV-2 RNA and candidate biomarkers in post-COVID-19 condition. Lancet Microbe 5, 100849 (2024).","journal-title":"Lancet Microbe"},{"key":"66073_CR90","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"66073_CR91","doi-asserted-by":"crossref","unstructured":"Megill, C. et al. cellxgene: a performant, scalable exploration platform for high dimensional sparse matrices. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2021.04.05.438318v1 (2021).","DOI":"10.1101\/2021.04.05.438318"},{"key":"66073_CR92","doi-asserted-by":"publisher","first-page":"D886","DOI":"10.1093\/nar\/gkae1142","volume":"53","author":"CZICS Program","year":"2025","unstructured":"Program, C. Z. I. C. S. et al. CZ CELLxGENE Discover: a single-cell data platform for scalable exploration, analysis and modeling of aggregated data. Nucleic Acids Res. 53, D886\u2013D900 (2025).","journal-title":"Nucleic Acids Res."},{"key":"66073_CR93","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e3529 (2021).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66073-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66073-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66073-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:03:34Z","timestamp":1766073814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66073-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66073"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66073-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5161132\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.N. and K.D. are mentioned as inventors on a patent application claiming the discovery and use of chimeric yellow fever\u2014Zika virus vaccines. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11221"}}